# Filing Detail

Form 10-Q - Quarterly report [Sections 13 or 15(d)]:
SEC Accession No. 0001193125-26-338078
Filing Date
2026-08-06
Accepted
2026-08-06 16:18:02
Documents
47
Period of Report
2026-06-30

Document Format Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
1 | 10-Q | janx-20260630.htm iXBRL | 10-Q | 2667341
2 | EX-31.1 | janx-ex31_1.htm | EX-31.1 | 18483
3 | EX-32.1 | janx-ex32_1.htm | EX-32.1 | 10303
| Complete submission text file | 0001193125-26-338078.txt |  | 10218603

Data Files

Seq | Description | Document | Type | Size
--- | --- | --- | --- | ---
4 | XBRL TAXONOMY EXTENSION SCHEMA WITH EMBEDDED LINKBASES DOCUMENT | janx-20260630.xsd | EX-101.SCH | 1007125
50 | EXTRACTED XBRL INSTANCE DOCUMENT | janx-20260630_htm.xml | XML | 2203192

Mailing Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130
Business Address 10955 VISTA SORRENTO PARKWAY SUITE 200 SAN DIEGO CA 92130 (858) 751-4493
Janux Therapeutics, Inc. (Filer) CIK: 0001817713 (see all company filings)

EIN.: 822289112 | State of Incorp.: DE | Fiscal Year End: 1231
Type: 10-Q | Act: 34 | File No.: 001-40475 | Film No.: 261249382
SIC: 2834 Pharmaceutical Preparations
(CF Office: 03 Life Sciences)